Pasar al contenido principal

NUEVOS AGENTES TERAPEUTICOS Y DE BIOIMAGEN BASADOS EN FLUOROFOROS COUPY

PID2020-117508RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

A near-infrared light-activatable Ru(ii)-coumarin photosensitizer active under hypoxic conditions

  • Ortega Forte, Enrique
  • Rovira, Anna
  • López Corrales, Marta
  • Hernández García, Alba
  • Ballester, Francisco José
  • Izquierdo García, Eduardo
  • Jordà-Redondo, Mireia
  • Bosch, Manel
  • Nonell, Santi
  • Santana, María Dolores
  • Ruiz, José
  • Marchán, Vicente
  • Gasser, Gilles
Photodynamic therapy (PDT) represents a promising approach for cancer treatment. However, the oxygen dependency of PDT to generate reactive oxygen species (ROS) hampers its therapeutic efficacy, especially against hypoxic solid tumors. In addition, some photosensitizers (PSs) have dark toxicity and are only activatable with short wavelengths such as blue or UV-light, which suffer from poor tissue penetration. Herein, we developed a novel hypoxia-active PS with operability in the near-infrared (NIR) region based on the conjugation of a cyclometalated Ru(II) polypyridyl complex of the type [Ru(C^N)(N^N)2] to a NIR-emitting COUPY dye. The novel Ru(II)-coumarin conjugate exhibits water-solubility, dark stability in biological media and high photostability along with advantageous luminescent properties that facilitate both bioimaging and phototherapy. Spectroscopic and photobiological studies revealed that this conjugate efficiently generates singlet oxygen and superoxide radical anions, thereby achieving high photoactivity toward cancer cells upon highly-penetrating 740 nm light irradiation even under hypoxic environments (2% O2). The induction of ROS-mediated cancer cell death upon low-energy wavelength irradiation along with the low dark toxicity exerted by this Ru(II)-coumarin conjugate could circumvent tissue penetration issues while alleviating the hypoxia limitation of PDT. As such, this strategy could pave the way to the development of novel NIR- and hypoxia-active Ru(II)-based theragnostic PSs fuelled by the conjugation of tunable, low molecular-weight COUPY fluorophores., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Achieving red-light anticancer photodynamic therapy under hypoxia using Ir(iii)–COUPY conjugates

  • Ortega-Forte, Enrique
  • Rovira, Anna
  • Ashoo, Pezhman
  • Izquierdo García, Eduardo
  • Hally, Cormac
  • Abad-Montero, Diego
  • Jordà-Redondo, Mireia
  • Vigueras Bautista, Gloria
  • Deyà, Alba
  • Hernández, José Luis
  • GALINO, JORGE
  • Bosch, Manel
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Ruiz, Jose
  • Marchán, Vicente
Despite the potential of photodynamic therapy (PDT), this oxygen-dependent oncological treatment is greatly restricted in the clinic by the well-known hypoxic feature of solid tumors. Here we provide new insights into the development of PDT agents based on conjugates between COUPY fluorophores and cyclometalated iridium(III) complexes with the aim of overcoming this limitation. The structural modifications carried out within the metal core of Ir(III)–COUPY conjugates, based on the incorporation of trifluorobenzyl groups at the cyclometalating ligands, enabled efficient exploitation of type I PDT mechanisms while retaining operativity under long-wavelength visible light, which facilitated deeper tissue penetration compared with short wavelengths. Photobiological evaluation revealed that Ir(III)–COUPY conjugate 3c achieved potent photocytotoxicity towards cisplatin-resistant ovarian (A2780cis) and mammary (EO771) cancer cell lines, efficiently photogenerated type I and type II ROS, and photoinduced apoptotic cell death using red light irradiation (620 nm). Importantly, this Ir(III)–COUPY conjugate retained such potent photoactivity under low-oxygen environment conditions (2% O2), delivering equipotent photocytotoxicity towards normoxic and hypoxic adherent cancer cells. Compound 3c was found to be highly phototoxic against EO771 multicellular tumor spheroids and showed no signs of toxicity or adverse effects in mice, which could facilitate in vivo phototherapeutic applications. Taken together, this study demonstrates that the conjugation between COUPY dyes and rationally designed Ir(III) complexes is a strategy at the frontier of the development of new red light-activated photosensitizers capable of operating under hypoxia, showing the promise of achieving satisfactory anticancer PDT effects., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Ruthenium(II) Polypyridyl Complexes Containing COUBPY Ligands as Potent Photosensitizers for the Efficient Phototherapy of Hypoxic Tumors

  • Abad-Montero, Diego
  • Gandioso, Albert
  • Izquierdo García, Eduardo
  • Chumillas, Sergi
  • Rovira, Anna
  • Bosch, Manel
  • Jordà-Redondo, Mireia
  • Castaño, Davor
  • Bonelli, Joaquín
  • Novikov, Valentin
  • Deyà, Alba
  • Hernández, José Luis
  • Galino, Jorge
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Gasser, Gilles
  • Marchán, Vicente
Hypoxia, a hallmark of many solid tumors, is linked to increased cancer aggressiveness, metastasis, and resistance to conventional therapies, leading to poor patient outcomes. This challenges the efficiency of photodynamic therapy (PDT), which relies on the generation of cytotoxic reactive oxygen species (ROS) through the irradiation of a photosensitizer (PS), a process partially dependent on oxygen levels. In this work, we introduce a novel family of potent PSs based on ruthenium(II) polypyridyl complexes with 2,2′-bipyridyl ligands derived from COUPY coumarins, termed COUBPYs. Ru-COUBPY complexes exhibit outstanding in vitro cytotoxicity against CT-26 cancer cells when irradiated with light within the phototherapeutic window, achieving nanomolar potency in both normoxic and hypoxic conditions while remaining nontoxic in the dark, leading to impressive phototoxic indices (>30,000). Their ability to generate both Type I and Type II ROS underpins their exceptional PDT efficiency. The lead compound of this study, SCV49, shows a favorable in vivo pharmacokinetic profile, excellent toxicological tolerability, and potent tumor growth inhibition in mice bearing subcutaneous CT-26 tumors at doses as low as 3 mg/kg upon irradiation with deep-red light (660 nm). These results allow us to propose SCV49 as a strong candidate for further preclinical development, particularly for treating large hypoxic solid tumors., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Mitochondria-Targeted COUPY Photocages: Synthesis and Visible-Light Photoactivation in Living Cells

  • López Corrales, Marta
  • Rovira, Anna
  • Gandioso, Albert
  • Nonell, Santi
  • Bosch, Manel
  • Marchán, Vicente
Releasing bioactive molecules in specific subcellular locations from the corresponding caged precursors offers great potential in photopharmacology, especially when using biologically compatible visible light. By taking advantage of the intrinsic preference of COUPY coumarins for mitochondria and their long wavelength absorption in the visible region, we have synthesized and fully characterized a series of COUPY-caged model compounds to investigate how the structure of the coumarin caging group affects the rate and efficiency of the photolysis process. Uncaging studies using yellow (560 nm) and red light (620 nm) in phosphate-buffered saline medium have demonstrated that the incorporation of a methyl group in a position adjacent to the photocleavable bond is particularly important to fine-tune the photochemical properties of the caging group. Additionally, the use of a COUPY-caged version of the protonophore 2,4-dinitrophenol allowed us to confirm by confocal microscopy that photoactivation can occur within mitochondria of living HeLa cells upon irradiation with low doses of yellow light. The new photolabile protecting groups presented here complement the photochemical toolbox in therapeutic applications since they will facilitate the delivery of photocages of biologically active compounds into mitochondria., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring structure-activity relationships in photodynamic therapy anticancer agents based on Ir(III)-COUPY conjugates

  • Rovira, Anna
  • Ortega-Forte, Enrique
  • Hally, Cormac
  • Jordà-Redondo, Mireia
  • Abad-Montero, Diego
  • Vigueras, Gloria
  • Martínez, Jesús I.
  • Bosch, Manel
  • Nonell, Santi
  • Ruiz, José
  • Marchán, Vicente
Photodynamic therapy holds great promise as a non-invasive anticancer tool against drug-resistant cancers. However, highly effective, non-toxic, and reliable photosensitizers with operability under hypoxic conditions remain to be developed. Herein, we took the advantageous properties of COUPY fluorophores and cyclometalated Ir(III) complexes to develop novel PDT agents based on Ir(III)-COUPY conjugates with the aim of exploring structure-activity relationships. The structural modifications carried out within the coumarin scaffold had a strong impact on the photophysical properties and cellular uptake of the conjugates. All Ir(III)-COUPY conjugates exhibited high phototoxicity under green light irradiation, which was attributed to the photogeneration of ROS, while remaining non-toxic in the dark. Among them, two hit conjugates showed excellent phototherapeutic indexes in cisplatin-resistant A2780cis cancer cells, both in normoxia and in hypoxia, suggesting that photoactive therapy approaches based on the conjugation of far-red/NIR-emitting COUPY dyes and transition metal complexes could effectively tackle in vitro acquired resistance to cisplatin., This work was supported by funds from the Spanish Ministerio de Ciencia e Innovación-Agencia Estatal de Investigación (MCI/AEI/10.13039/501100011033) and FEDER funds (Projects CTQ2017-84779-R, RTI2018-096891-B-I00, PID2020-117508RB-I00, PID2021-122850NB-I00, CTQ2016-78454-C2-1-R, and PID2020-115801RB-C22)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Exploring structure–activity relationships in photodynamic therapy anticancer agents based on Ir(III)-COUPY conjugates

  • Rovira, A.
  • Ortega-Forte, E.
  • Hally, C.
  • Jordà-Redondo, M.
  • Abad-Montero, D.
  • Vigueras, G.
  • Martínez, J. I.
  • Bosch, M.
  • Nonell, S.
  • Ruiz, J.
  • Marchán, V.
Photodynamic therapy holds great promise as a non-invasive anticancer tool against drug-resistant cancers. However, highly effective, non-toxic, and reliable photosensitizers with operability under hypoxic conditions remain to be developed. Herein, we took the advantageous properties of COUPY fluorophores and cyclometalated Ir(III) complexes to develop novel PDT agents based on Ir(III)-COUPY conjugates with the aim of exploring structure–activity relationships. The structural modifications carried out within the coumarin scaffold had a strong impact on the photophysical properties and cellular uptake of the conjugates. All Ir(III)-COUPY conjugates exhibited high phototoxicity under green light irradiation, which was attributed to the photogeneration of ROS, while remaining non-toxic in the dark. Among them, two hit conjugates showed excellent phototherapeutic indexes in cisplatin-resistant A2780cis cancer cells, both in normoxia and in hypoxia, suggesting that photoactive therapy approaches based on the conjugation of far-red/NIR-emitting COUPY dyes and transition metal complexes could effectively tackle in vitro acquired resistance to cisplatin.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mitochondria-Targeted COUPY Photocages: Synthesis and Visible-Light Photoactivation in Living Cells

  • López Corrales, Marta
  • Rovira, Anna
  • Gandioso, Albert
  • Nonell, Santi
  • Bosch, Manel
  • Marchán, Vicente
Releasing bioactive molecules in specific subcellular locations from the corresponding caged precursors offers great potential in photopharmacology, especially when using biologically compatible visible light. By taking advantage of the intrinsic preference of COUPY coumarins for mitochondria and their long wavelength absorption in the visible region, we have synthesized and fully characterized a series of COUPY-caged model compounds to investigate how the structure of the coumarin caging group affects the rate and efficiency of the photolysis process. Uncaging studies using yellow (560 nm) and red light (620 nm) in phosphate-buffered saline medium have demonstrated that the incorporation of a methyl group in a position adjacent to the photocleavable bond is particularly important to fine-tune the photochemical properties of the caging group. Additionally, the use of a COUPY-caged version of the protonophore 2,4-dinitrophenol allowed us to confirm by confocal microscopy that photoactivation can occur within mitochondria of living HeLa cells upon irradiation with low doses of yellow light. The new photolabile protecting groups presented here complement the photochemical toolbox in therapeutic applications since they will facilitate the delivery of photocages of biologically active compounds into mitochondria., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Ruthenium(II) Polypyridyl Complexes Containing COUBPY Ligands as Potent Photosensitizers for the Efficient Phototherapy of Hypoxic Tumors

  • Abad-Montero, Diego
  • Gandioso, Albert
  • Izquierdo García, Eduardo
  • Chumillas, Sergi
  • Rovira, Anna
  • Bosch, Manel
  • Jordà-Redondo, Mireia
  • Castaño, Davor
  • Bonelli, Joaquín
  • Novikov, Valentin
  • Deyà, Alba
  • Hernández, José Luis
  • Galino, Jorge
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Gasser, Gilles
  • Marchán, Vicente
Hypoxia, a hallmark of many solid tumors, is linked to increased cancer aggressiveness, metastasis, and resistance to conventional therapies, leading to poor patient outcomes. This challenges the efficiency of photodynamic therapy (PDT), which relies on the generation of cytotoxic reactive oxygen species (ROS) through the irradiation of a photosensitizer (PS), a process partially dependent on oxygen levels. In this work, we introduce a novel family of potent PSs based on ruthenium(II) polypyridyl complexes with 2,2′-bipyridyl ligands derived from COUPY coumarins, termed COUBPYs. Ru-COUBPY complexes exhibit outstanding in vitro cytotoxicity against CT-26 cancer cells when irradiated with light within the phototherapeutic window, achieving nanomolar potency in both normoxic and hypoxic conditions while remaining nontoxic in the dark, leading to impressive phototoxic indices (>30,000). Their ability to generate both Type I and Type II ROS underpins their exceptional PDT efficiency. The lead compound of this study, SCV49, shows a favorable in vivo pharmacokinetic profile, excellent toxicological tolerability, and potent tumor growth inhibition in mice bearing subcutaneous CT-26 tumors at doses as low as 3 mg/kg upon irradiation with deep-red light (660 nm). These results allow us to propose SCV49 as a strong candidate for further preclinical development, particularly for treating large hypoxic solid tumors., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Achieving red-light anticancer photodynamic therapy under hypoxia using Ir(iii)–COUPY conjugates

  • Ortega-Forte, Enrique
  • Rovira, Anna
  • Ashoo, Pezhman
  • Izquierdo García, Eduardo
  • Hally, Cormac
  • Abad-Montero, Diego
  • Jordà-Redondo, Mireia
  • Vigueras Bautista, Gloria
  • Deyà, Alba
  • Hernández, José Luis
  • GALINO, JORGE
  • Bosch, Manel
  • Alberto, Marta Erminia
  • Francés-Monerris, Antonio
  • Nonell, Santi
  • Ruiz, Jose
  • Marchán, Vicente
Despite the potential of photodynamic therapy (PDT), this oxygen-dependent oncological treatment is greatly restricted in the clinic by the well-known hypoxic feature of solid tumors. Here we provide new insights into the development of PDT agents based on conjugates between COUPY fluorophores and cyclometalated iridium(III) complexes with the aim of overcoming this limitation. The structural modifications carried out within the metal core of Ir(III)–COUPY conjugates, based on the incorporation of trifluorobenzyl groups at the cyclometalating ligands, enabled efficient exploitation of type I PDT mechanisms while retaining operativity under long-wavelength visible light, which facilitated deeper tissue penetration compared with short wavelengths. Photobiological evaluation revealed that Ir(III)–COUPY conjugate 3c achieved potent photocytotoxicity towards cisplatin-resistant ovarian (A2780cis) and mammary (EO771) cancer cell lines, efficiently photogenerated type I and type II ROS, and photoinduced apoptotic cell death using red light irradiation (620 nm). Importantly, this Ir(III)–COUPY conjugate retained such potent photoactivity under low-oxygen environment conditions (2% O2), delivering equipotent photocytotoxicity towards normoxic and hypoxic adherent cancer cells. Compound 3c was found to be highly phototoxic against EO771 multicellular tumor spheroids and showed no signs of toxicity or adverse effects in mice, which could facilitate in vivo phototherapeutic applications. Taken together, this study demonstrates that the conjugation between COUPY dyes and rationally designed Ir(III) complexes is a strategy at the frontier of the development of new red light-activated photosensitizers capable of operating under hypoxia, showing the promise of achieving satisfactory anticancer PDT effects., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A near-infrared light-activatable Ru(ii)-coumarin photosensitizer active under hypoxic conditions

  • Ortega Forte, Enrique
  • Rovira, Anna
  • López Corrales, Marta
  • Hernández García, Alba
  • Ballester, Francisco José
  • Izquierdo García, Eduardo
  • Jordà-Redondo, Mireia
  • Bosch, Manel
  • Nonell, Santi
  • Santana, María Dolores
  • Ruiz, José
  • Marchán, Vicente
  • Gasser, Gilles
Photodynamic therapy (PDT) represents a promising approach for cancer treatment. However, the oxygen dependency of PDT to generate reactive oxygen species (ROS) hampers its therapeutic efficacy, especially against hypoxic solid tumors. In addition, some photosensitizers (PSs) have dark toxicity and are only activatable with short wavelengths such as blue or UV-light, which suffer from poor tissue penetration. Herein, we developed a novel hypoxia-active PS with operability in the near-infrared (NIR) region based on the conjugation of a cyclometalated Ru(II) polypyridyl complex of the type [Ru(C^N)(N^N)2] to a NIR-emitting COUPY dye. The novel Ru(II)-coumarin conjugate exhibits water-solubility, dark stability in biological media and high photostability along with advantageous luminescent properties that facilitate both bioimaging and phototherapy. Spectroscopic and photobiological studies revealed that this conjugate efficiently generates singlet oxygen and superoxide radical anions, thereby achieving high photoactivity toward cancer cells upon highly-penetrating 740 nm light irradiation even under hypoxic environments (2% O2). The induction of ROS-mediated cancer cell death upon low-energy wavelength irradiation along with the low dark toxicity exerted by this Ru(II)-coumarin conjugate could circumvent tissue penetration issues while alleviating the hypoxia limitation of PDT. As such, this strategy could pave the way to the development of novel NIR- and hypoxia-active Ru(II)-based theragnostic PSs fuelled by the conjugation of tunable, low molecular-weight COUPY fluorophores., info:eu-repo/semantics/publishedVersion